|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
2010-10-28
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
It has been suggested that clopidogrel may be less effective in reducing the rate of cardiovascular events among persons who are carriers of loss-of-function CYP2C19 alleles that are associated with reduced conversion of clopidogrel to its active metabolite.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1533-4406
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
28
|
|
pubmed:volume |
363
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1704-14
|
|
pubmed:dateRevised |
2011-3-3
|
|
pubmed:meshHeading |
pubmed-meshheading:20979470-Acute Coronary Syndrome,
pubmed-meshheading:20979470-Aged,
pubmed-meshheading:20979470-Aryl Hydrocarbon Hydroxylases,
pubmed-meshheading:20979470-Atrial Fibrillation,
pubmed-meshheading:20979470-Female,
pubmed-meshheading:20979470-Genotype,
pubmed-meshheading:20979470-Hemorrhage,
pubmed-meshheading:20979470-Humans,
pubmed-meshheading:20979470-Male,
pubmed-meshheading:20979470-Middle Aged,
pubmed-meshheading:20979470-Mutation,
pubmed-meshheading:20979470-Platelet Aggregation Inhibitors,
pubmed-meshheading:20979470-Ticlopidine,
pubmed-meshheading:20979470-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.
|
|
pubmed:affiliation |
Population Health Research Institute, Hamilton Health Sciences, Hamilton, ON, Canada. pareg@mcmaster.ca
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
